Search

The authors have studied the long-term effects of combined oestrogen-progestogen on the secretion of gonadotrophins and on ovarian function. Estimation of the radio-immune levels of the plasma concentrations of the pituitary luteinizing hormone (LH), of oestradiol (E2), of progesterone (P) and of 20 alpha hydroxyprogesterone (20 alpha OHP) and of testosterone (T) served as a base for this study. A test cycle and 8 cycles in which a combination of 50 micrograms of ethinyl-oestradiol and 0.5 mg of norgestrel were administered were studied in 4 normal volunteer women. A pituitary stimulation test using 50 micrograms of gonadotrophin "releasing factor" (LH-RH) was given during the 7th cycle. Ovarian stimulation using human menopausal gonadotrophins (HMG) was given during the 8th cycle of treatment in 3 of the women and in 3 other subjects. Pituitary secretion of LH and ovarian secretion of E2 and P are partially inhibited. Pituitary response to the injection of LH-RH stays normal but 5 out 6 patients had no response to stimulation by gonadotrophins. These results allow us to conclude that the lowering of production of gonadotrophins during treatment with combination oestrogen and progestagens is responsible for inhibition of ovarian activity, and that there is a delay before the latter respond to stimulation by either endogenous or exogenous gonadotrophins.

The authors have studied in particular hepatitis B virus markers and the ratio of OKT4+/OKT8+ cells in two subgroups of 52 deprived asymptomatic drug addicts. In the group 1 (deprived for 19 days on an average), 52% of the subjects showed a ratio of OKT4+/OKT8+ less than 1, whereas in the group 2 (deprived for 30 months on an average), this percentage is only of 25%. HBV markers were present in 90% of the subjects in each group. We would like to point out the high frequency of the anti-HBc positivity without other markers in these two groups, respectively 20% in the group 1 and 32% in the group 2. These results emphasize the interest in screening systematically this marker in all blood donors.

An inquiry conducted in all the French blood transfusion centres from the 1st of July, 1985 to the 31st of March, 1986 in respect of blood donations confirmed to be positive for anti-HIV antibodies has given the following results: prevalence of 0.59 per thousand (1661/2,809,744); significant difference between first-time and regular blood donors (2.04% and 0.39% respectively); predominance of males (85%); 65% are less than 30 years old; the main risk factors are homosexuality (49%) and the use of I.V. drugs (28%).

The authors looked for Australia antigen in a population of 578 rheumatic patients, 300 of whom were polyarthritic, by electrosyneresis and complement fixation methods. Australia antigen was found in 26 patients, and anti-Australia antibodies in 33 patients. Most of these patients were suffering from rheumatoid polyarthritis--22 presented hepatic disturbance, and 28 had undergone surgical operations, blood transfusions, and repeated hospitalization. The presence of Australia antigen did not in any case appear to play a role in the development of the lesions, apart from the occurrence of signs of hepatic lesions, but appeared to be an indicator of a form of hospitalization.